Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>wow! 35% year over year even w/ Baraclude in the mix...if anything, i thot Hepsera sales would fall off some.<

Hepsera’s market share is declining, but sales are nonetheless growing rapidly because the HBV market is growing even faster (#msg-18909904).

1Q07 Baraclude sales will be announced by BMY on April 26, the same day IDIX reports its own 1Q07 numbers.